What is known and Objective: Literature evidence suggests leukotriene involvement in the pathogenesis of atopic dermatitis. This article aimed to discuss whether the offlabel use of montelukast, a leukotriene receptor antagonist, is justifiable for the treatment of atopic dermatitis.
| WHAT IS KNOWN AND OBJECTIVE
Atopic dermatitis (AD) is a chronically relapsing eczematous skin disorder characterized by inflammation and pruritus, with concurrent cutaneous physiological dysfunctions, including xerosis. [1] [2] [3] The present standard therapies for mild AD include the use of topical corticosteroids for inflammation and the regular application of emollients. For moderate-to-severe cases, short-term use of systemic oral glucocorticoids or other steroid-sparing immunosuppressive agents, such as cyclosporine A, azathioprine and methotrexate is warranted in addition to the treatments mentioned above. 4 Leukotrienes (LTs) are potent biological pro-inflammatory mediators derived from arachidonic acid through the 5-lipoxygenase pathway. 5 Basophils, mast cells and eosinophils play a major role in the production of biological LTs. 5 Leukotrienes are classified into two groups, those with the presence of a sulphur bond linkage (cysteinyl LTs: LTC4, LTD4, LTE4) and those that do not (LTB4). 5 Comparing to healthy subjects, it is reported that patients with AD exhibit increased spontaneous releasability of LTs from their leucocytes. 6 In support of that, by employing the suction blister technique, LTC4 has been found in the skin of patients with AD. 7 Also, absolute eosinophil count, an important source of LTs, has been shown to be positively correlated with the severity of the skin disorder. 8 In addition, it is reported that patients with AD of higher severity have increased activated circulating basophils in vivo and enhanced basophil releasability of LTs, as compared to healthy volunteers. 9 Furthermore, increased urinary concentrations of LTE4, a stable metabolite of LTC4 and LTD4, and being an essential indicator of whole-body cysteinyl LT production in vivo, have also been noted in patients with AD. 10 All these results
collectively support the association of the leukotriene pathway with pathogenesis of AD.
Montelukast is an orally administered, cysteinyl-leukotriene-1 receptor antagonist (LTRA) that is approved by the FDA for the prophylaxis and chronic treatment of bronchial asthma and allergic rhinitis. [11] [12] [13] Due to the common association of atopic dermatitis with asthma and allergic rhinitis, or what is collectively known as the "atopic triad," the improvement of atopic eczema was anecdotally reported in patients receiving montelukast to control the manifestations of airway diseases. 1 In fact, the review paper by Nettis et al 2 concluded
that clinicians should try montelukast in all cases of AD unresponsive to conventional treatments. This article aimed to discuss whether the off-label use of montelukast is justifiable for the treatment of atopic dermatitis.
| COMMENT

| Evidence from non-randomized studies
In 2001 Hon et al, 17 who studied the benefits of montelukast in seven paediatric patients with ages ranging from 3 to 16 years, also reported a positive response based on the reduction in SCORAD index. This is a severity score for AD based on three assessed components: intensity, extent (ie body surface area affected by AD) and subjective symptoms (ie itch and sleeplessness) of the skin disorder. 18 The total SCORAD score decreased in five patients, ranging from a 30% to 84% reduction, whereas no differences were observed in the other two patients. It is worth noted that only the intensity score was reduced, while the disease extent and subjective symptoms remained the same. This result showed inconsistency with the previous two case series which reported the antipruritic effect of montelukast. Silverberg et al 19 could not replicate the same therapeutic effects in 7 studied patients and demonstrated no sustained benefit of montelukast for patients with extensive AD that was refractory to oral antihistamines and mid-tohigh potency topical steroids.
The results from these non-randomized studies supported the use of montelukast for AD treatment with the exception of one study by
Silverberg et al. 19 However, evidence from these studies should be interpreted with caution as it is relatively weak due to the absence of randomization, control groups and blinding processes, subjecting the results to high risk of selection and reporting biases. Furthermore, the sample sizes of the studies were very small. patients and could not show any significant differences between the montelukast and placebo groups in terms of SCORAD score and urinary LTE4. This is consistent with another trial outcome by Veien et al 27 (n = 59 subjects), in which concomitant active topical or systemic treatment was strictly not permitted during the interventional period.
| Evidence from randomized clinical trials (RCTs)
Friedmann et al 28 confirmed this outcome in a parallel-group trial with 54 evaluable subjects. In fact, he found that the improvement in the montelukast group was slightly inferior to that in the placebo group, demonstrating how prominent the placebo effect can be in atopic dermatitis trials. This result also concurred with the findings obtained by
Lehtimaki et al, 29 who recruited 49 pollen-sensitized subjects experiencing allergic symptoms from both the upper and lower airways, and allergic symptoms outside the airways (conjunctivitis, eczema and/or urticaria). The authors found no significant improvement with montelukast in allergic symptoms outside the airways in patients suffering different manifestations of the atopic syndrome.
In addition, four published RCTs, including a cross-over study by
Ehlayel et al, 30 compared the amounts of rescue medications (oral antihistamines, topical steroids and oral antibiotics) required by patients from treatment (montelukast) and control groups. No significant differences were observed, demonstrating the limited potential of montelukast as an adjunct therapy for atopic dermatitis as well.
The inconsistent findings across the RCTs may be related to the limited number of patients, nuances in study design, the varying severity of disease and the concomitant use of steroids in some of the studies. Interestingly, all the studies with positive findings had relatively small sample sizes, suggesting the possibility of type II errors due to the limited sample size and power.
| WHAT IS NEW AND CONCLUSION
The current clinical data suggest that montelukast has very limited efficacy in the overall amelioration of clinical manifestations of AD. 4 In most of the RCTs that exhibited a positive response, montelukast was only shown to be a good antipruritic agent, with minor to no significant differences observed in the other measured primary outcomes, in particular the body surface area affected by AD. Therefore, the offlabel use of montelukast in treating AD should not be recommended in the clinical setting at this time. This is to avoid the delay in the provision of more effective conventional treatments (ie optimal skin hydration, use of corticosteroid creams and, for moderate-to-severe conditions, the use of steroid-sparing immune suppressants). 
